Cumulative Sales as of November, 10.1% Growth Compared to Previous Year
Hanmi Pharm announced on the 14th that it has secured its position as the No. 1 domestic pharmaceutical company by recording 843.7 billion KRW in domestic outpatient prescription sales by the end of November this year.
This result is based on the data compiled by the pharmaceutical market research firm UBIST. UBIST calculates this by collecting prescription dispensing data from pharmacy panels, including the quantity of medicines prescribed by doctors and sales amounts.
Hanmi Pharm's outpatient prescription sales this year grew by 10.1% compared to the same period last year. Excluding 2020, when the COVID-19 pandemic fully began, Hanmi Pharm explained that it has achieved over 10% growth annually for the past five years.
Hanmi Pharm evaluated that this achievement is significant because it was made through 'product sales' developed and sold independently using proprietary technology. This means that the profits earned from product sales are continuously reinvested in research and development (R&D) for new drug development, establishing a 'Korean-style R&D virtuous cycle model.'
The company attributed this success to the strong performance of the combination drug for dyslipidemia treatment, 'Rosuzet,' and the antihypertensive drug family, 'Amozantan Family.' Rosuzet, which recorded 149.9 billion KRW in prescription sales last year, achieved 162.8 billion KRW in prescription sales by November this year, growing approximately 20%. The four products in the Amozantan Family recorded sales of 129.8 billion KRW by November this year. The four-drug combination for patients with both hypertension and dyslipidemia, 'Amozantan XQ (Amozantan + Rosuzet),' is expected to surpass 10 billion KRW in prescription sales for the first time this year.
Additionally, by November this year, sales included ▲Esomezol (gastroesophageal reflux disease) at 56.5 billion KRW ▲Hanmi Tams (benign prostatic hyperplasia) at 36.8 billion KRW ▲Naxozol (anti-inflammatory analgesic) at 24.6 billion KRW. Non-reimbursed drugs Palpal (erectile dysfunction) and Gugu (erectile dysfunction/benign prostatic hyperplasia) also recorded sales of 38.8 billion KRW and 19.7 billion KRW, respectively.
A Hanmi Pharm official stated, "Our unique formulation technology and accumulated unmatched competitiveness have led to the record of being No. 1 in outpatient prescription sales for six consecutive years. We thank all domestic medical professionals who trust Hanmi’s product competitiveness and excellence, as well as the patients who rely on Hanmi products."
The official added, "While continuously developing 'better products' that dramatically improve patients' quality of life, we will also build more solid clinical evidence to advance as a leading R&D-focused pharmaceutical company representing Korea."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
